Prosecution Insights
Last updated: November 04, 2026
Application No. 18/541,626

COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC N-ALKYLAMIDE AS ACTIVE SUBSTANCE AND ITS MANUFACTURING PROCESS

Final Rejection §102§103
Filed
Dec 15, 2023
Priority
Dec 16, 2022 — BE 2022/6030
Examiner
SASAN, ARADHANA
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tilman
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
732 granted / 1131 resolved
+4.7% vs TC avg
Strong +26% interview lift
Without
With
+26.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
29 currently pending
Career history
1182
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
46.0%
+6.0% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
17.7%
-22.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1131 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application The Amendments and Remarks filed on 08/06/26 are acknowledged. Claims 1, 2, 4, and 13 were amended. New claims 15-20 were added. Claims 7-12 and 14 were previously withdrawn from consideration. Claims 1-20 are pending. Claims 1-6, 13, and 15-20 are included in the prosecution. Applicants’ request for rejoinder of the withdrawn claims based on MPEP 821.04 is acknowledged. Priority Receipt is acknowledged of the certified English translation of the foreign priority document BE 2022/6030, which was submitted on 08/06/26. Response to Amendments/Arguments Objection to the Specification In light of the amendment of the Specification, the objection to the disclosure is withdrawn. Claim Objection(s) In light of the amendment of claim 4, the objection to this claim is withdrawn. However, new claim objections are presented below. Claim Objections Claims 15 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Notice for all US Patent Applications filed on or after March 16, 2013 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Maintained Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-6 and 13 are again rejected under 35 U.S.C. 102(a)(1) as being anticipated by Anastasiou et al. (US 2013/0216649 A1 – “Anastasiou”). Instant claim 1 is drawn to a composition in the form of a thermoformed extrudate in any suitable form allowing administration to an animal or a human being, the composition comprising at least one natural or synthetic N-alkylamide as active substance and at least one support of natural origin chosen from the group consisting of amino acids, peptides, polypeptides, proteins, saccharides, lipids, their derivatives and their mixtures, wherein the composition exhibits a higher solubility and/or dispersion of the at least one natural or synthetic N-alkylamide than the solubility and/or dispersion of said N-alkylamide in isolation. Anastasiou teaches a chewing gum composition comprising spilanthol, which is a natural N-alkylamide (Abstract, [0009], claims 1-18). Maltodextrin having a dextrose equivalent (DE) between 10 and 18, and mixtures thereof with hydrogenated starch hydrolysates, can be used as the matrix carriers of the extruded spilanthol-containing component in powder form ([0040], Example 1 – [0159], TABLE 1). The mixture of components is formed into the desired final shape by employing conventional techniques, e.g., extruded ([0161]). Regarding instant claims 1 and 2, the limitations of a composition in the form of a thermoformed extrudate in any suitable form allowing administration to an animal or a human being is anticipated by the extruded chewing gum composition ([0161]), as taught by Anastasiou. Regarding instant claims 1 and 2-3, the limitations of at least one natural or synthetic N-alkylamide as active substance are anticipated by the spilanthol, which is a natural N-alkylamide (Abstract, [0009], [0040], Example 1 – [0159], TABLE 1, claims 1-18), as taught by Anastasiou. Regarding instant claim 1, the limitation of at least one support of natural origin chosen from the group consisting of amino acids, peptides, polypeptides, proteins, saccharides, lipids, their derivatives and their mixtures is anticipated by the maltodextrin ([0040], [0059]), monosaccharides, disaccharides, polysaccharides, sugar alcohols, and polydextrose ([0059]), as taught by Anastasiou. Regarding instant claim 1, the newly added limitation of the composition exhibiting a higher solubility and/or dispersion of the at least one natural or synthetic N-alkylamide than the solubility and/or dispersion of said N-alkylamide in isolation is anticipated by the extruded chewing gum composition ([0161]), spilanthol, which is a natural N-alkylamide (Abstract, [0009], [0040], Example 1 – [0159], TABLE 1, claims 1-18), and the maltodextrin ([0040], [0059]), monosaccharides, disaccharides, polysaccharides, sugar alcohols, and polydextrose ([0059]), as taught by Anastasiou. The recited limitation of a higher solubility and/or dispersion is a property associated with the composition and is inseparable from it. Instant claim 1 does not recite any structural features such as specific N-alkylamide, support of natural origin or their corresponding concentrations to distinguish over the thermoformed extrudate containing spilanthol as well as maltodextrin, monosaccharides, disaccharides, polysaccharides, sugar alcohols and polydextrose which are taught by Anastasiou. Please see MPEP 2112.01. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990.) The burden is shifted to Applicant to show that the prior art product does not possess or render obvious the same properties as the instantly claimed product. Regarding instant claim 4, the limitation of at least one plasticizing agent is anticipated by the plasticizers including lanolin, palmitic acid, etc., ([0055], [0062], [0064]), as taught by Anastasiou. Regarding instant claim 5, the limitation of at least one additive is anticipated by the surfactant ([0064], [0143]), antioxidants ([0054], [0070], [0123], [0139]), and chelating agent ([0064], [0143]), as taught by Anastasiou. Regarding instant claim 6, the limitation of at least one first additional compound of polyphenol type is anticipated by the polyphenols and flavonoids ([0140]), as taught by Anastasiou. Regarding instant claim 13, the limitation of any suitable form allowing administration to an animal or a human being is anticipated by the extruded chewing gum composition ([0161]), as taught by Anastasiou. The limitation of “for use in preventive and/or curative treatment …” denotes a future-intended use and thus, does not accord patentable weight to the claims. The recited intended use does not alter the structure of the claimed composition. Response to Arguments Applicant’s arguments (Pages 9-10, filed 08/06/26) with respect to the rejection of claims 1-6 and 13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Anastasiou have been fully considered but are not persuasive. Applicant argues that Anastasiou does not teach a composition with spilanthol having a higher solubility and/or dispersion than spilanthol in isolation. This is not persuasive because, as explained above, the recited limitation of a higher solubility and/or dispersion is a property associated with the composition and is inseparable from it. Instant claim 1 does not recite any structural features such as specific N-alkylamide, support of natural origin or their corresponding concentrations to distinguish over the thermoformed extrudate containing spilanthol as well as maltodextrin, monosaccharides, disaccharides, polysaccharides, sugar alcohols and polydextrose taught by Anastasiou. Please see MPEP 2112.01. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990.) The burden is shifted to Applicant to show that the prior art product does not possess or render obvious the same properties as the instantly claimed product. Moreover, the instant specification shows that the higher solubility and/or dispersion is achieved with a specific natural or synthetic N-alkylamide and a specific support of natural origin at specific concentrations. Example 2 a) uses 180 mg of palmitoylethanolamide (PEA) ([0177]) and b) uses 180 mg of oleoylethanolamide (OEA) ([0183]). Figure 1 shows the dispersion and solubility for inventive compositions containing PEA that are greater than control ([0180]); and Figure 2 shows the dispersion and solubility for inventive compositions containing OEA that are greater than control ([0186]). However, instant claim 1 does not recite a specific N-alkylamide or support of natural origin or their corresponding concentrations to distinguish over the thermoformed extrudate taught by Anastasiou. Therefore, the rejection of 05/06/26 is maintained. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were effectively filed absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned at the time a later invention was effectively filed in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 3 is again rejected under 35 U.S.C. 103 as being unpatentable over Anastasiou et al. (US 2013/0216649 A1 – “Anastasiou”), as applied to claims 1-6 and 13 above, in view of Taglienti et al. (US 2020/0046759 A1 – “Taglienti”). The elected species of natural or synthetic N-alkylamide is palmitoylethanolamide. The teaching of Anastasiou is discussed above. Although Anastasiou teaches spilanthol, which is a natural N-alkylamide (Abstract, [0009], claims 1-18), Anastasiou does not expressly teach the elected species of palmitoylethanolamide. Taglienti teaches a sustained-release matrix prepared by melt-extrusion techniques ([0151], [0169]), wherein the active ingredient includes palmitoylethanolamide ([0158]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to prepare a thermoformed extrudate which is an extruded chewing gum composition that contains a natural N-alkylamide, i.e., spilanthol, as taught by Anastasiou, substitute the spilanthol with palmitoylethanolamide, as taught by Taglienti, and produce the instant invention. One of ordinary skill in the art would have been motivated to do this because both references teach extruded products containing natural N-alkylamides. The simple substitution of one known element for another to obtain predictable results is obvious. Please see MPEP 2141(III)(B). One of ordinary skill in the art would have found it obvious to use various N-alkylamides based on the desired therapy of the composition, including those taught by Anastasiou and Taglienti. One of ordinary skill in the art would also have been motivated to use the palmitoylethanolamide of Taglienti because this reference teaches that this N-alkylamide is a cannabinoid receptor agonist ([0158]). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Regarding instant claim 3, the limitation of the elected species of palmitoylethanolamide would have been obvious over the palmitoylethanolamide ([0158]), as taught by Taglienti. Response to Arguments Applicant’s arguments (Page 10, filed 08/06/26) with respect to the rejection of claim 3 under 35 USC § 103 as being unpatentable over Anastasiou in view of Taglienti have been fully considered but are not persuasive. Applicant argues that “Taglienti does not teach a composition with palmitoylethanolamide having a higher solubility and/or dispersion than palmitoylethanolamide in isolation. Thus, Taglienti, like Anastasiou, does not describe a composition exhibiting a higher solubility and/or dispersion of at least one natural or synthetic N-alkylamide than the solubility and/or dispersion of said N-alkylamide in isolation.” This is not persuasive because, as explained above, the recited limitation of a higher solubility and/or dispersion is a property associated with the composition and is inseparable from it. Please see MPEP 2112.01. The instant specification shows that the higher solubility and/or dispersion is achieved with a specific natural or synthetic N-alkylamide and a specific support of natural origin at specific concentrations. Example 2 a) uses 180 mg of palmitoylethanolamide (PEA) ([0177]) and b) uses 180 mg of oleoylethanolamide (OEA) ([0183]). Figure 1 shows the dispersion and solubility for inventive compositions containing PEA that are greater than control ([0180]); and Figure 2 shows the dispersion and solubility for inventive compositions containing OEA that are greater than control ([0186]). However, instant claims do not recite a specific N-alkylamide or support of natural origin or their corresponding concentrations to distinguish over the thermoformed extrudate taught by Anastasiou. Please see MPEP 2145. Furthermore, MPEP 716.02(d) states: “Whether the unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the “objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support.”” Therefore, the rejection of 05/06/26 is maintained. Allowable Subject Matter An updated prior art search did not uncover references which teach the subject matter recited in claims 15-20. Therefore, claims 15-20 contain allowable subject matter. Conclusion Claims 17-20 are allowable. Claims 15-16 are objected to. Claims 1-6 and 13 are rejected. Claims 7-12 and 14 are withdrawn. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ARADHANA SASAN whose telephone number is (571)272-9022. The examiner can normally be reached Monday to Friday from 6:30 am to 3:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached on 571-272-6023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ARADHANA SASAN/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Dec 15, 2023
Application Filed
May 06, 2026
Non-Final Rejection mailed — §102, §103
Aug 06, 2026
Response Filed
Oct 15, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747085
ANTIMICROBIAL BOTTLE WITH ANTIMICROBIAL SEAL
2y 7m to grant Granted Sep 29, 2026
Patent 12734204
COMPOSITION FOR ANTI-OBESITY AND PREVENTING OR TREATING MUSCLE LOSS, CONTAINING CATECHIN GLYCOSIDE EXTRACT DERIVED FROM PLANT IN GENUS ULMUS AS ACTIVE INGREDIENT
3y 3m to grant Granted Sep 15, 2026
Patent 12728110
MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
11m to grant Granted Sep 08, 2026
Patent 12691071
LACOSAMIDE PHARMACEUTICAL COMPOSITION PREPARATION METHOD AND APPLICATIONS THEREOF
2y 10m to grant Granted Jul 28, 2026
Patent 12678500
PATHOGEN DESTRUCTION SYSTEM AND METHOD USING MAGNETIC MARKERS
4y 1m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
91%
With Interview (+26.0%)
3y 1m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1131 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month